Table 6 Weekly Dosing Assumption for Adalimumab: Comparison of Mean PASI Score, BSA Reduction, and Treatment Cost in Psoriasis Patients on Risankizumab (N = 30) vs. Adalimumab (N = 40)
| Â | Risankizumab | Adalimumab | Mean difference (95% confidence interval) |
|---|---|---|---|
Cost of treatment (USD), mean ± SD | 16638.33 ± 5086.63 | 16120.52 ± 1039.43 | 517.81(–567.699–2525.28) |
Difference in PASI (%) | 87.373 ± 25.938 | 74.499 ± 36.143 | 12.88(1.271–24.934) |